Biogen
NEWS
Additional findings from Biogen’s Phase II LILAC study, announced today, show the company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus.
Biogen originally announced the initiation of its Phase II clinical trial, AFFINITY, designed to evaluate opicinumab back in 2017. The drug was being examined as an investigational add-on therapy for patients with relapsing MS.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
A new, 64-page study that has not been peer-reviewed, extrapolates the number of infections that stemmed from the company’s corporate meeting held at the Marriott Long Wharf hotel in February.
Biogen recently announced plans to initiate a Phase IV clinical trial to determine the benefit of Spinraza in patients who received Zolgensma. The two therapies have markedly different ways of treating the disease.
The FDA set a PDUFA target date of March 7, 2021 for aducanumab, Biogen said.
Biogen and Denali Therapeutics inked a binding deal to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
JOBS
IN THE PRESS